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Background: We compared the effects of atorvastatin on glucose metabolism and insulin sensitivity in hypercholesterolemic patients with and 
without metabolic syndrome/diabetes.
Methods: Randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched. Forty-four patients were given 
on placebo and 42, 44, 43, and 40 patients were given daily on atorvastatin 10, 20, 40, and 80 mg, respectively during a 2 month treatment period. 
Nineteen patients on placebo and 18, 18, 20, and 18 patients on atorvastatin 10, 20, 40, and 80 mg were metabolic syndrome/diabetes.
Results: Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol (median % changes; 39, 47, 52, and 54%) and apolipoprotein 
B levels (31, 37, 44, and 48%) after 2 months therapy when compared with baseline (all P<0.001 by paired t-test) or when compared with placebo 
(P<0.001 by ANOVA). Atorvastatin 10, 20, 40, and 80 mg significantly increased insulin (27, 63, 36, and 58%) and glycated hemoglobin levels (4, 7, 
7, and 8%) from baseline (all P<0.05 by paired t-test) or when compared with placebo (P=0.011 for insulin and P=0.004 for glycated hemoglobin by 
ANOVA). Atorvastatin 10, 20, 40, and 80 mg decreased plasma adiponectin levels (0, 18, 2, and 11%) and decreased insulin sensitivity (2, 6, 4, and 
6%) when compared with baseline (P=0.732, P=0.024, P=0.508, and P=0.128 for adiponectin; P=0.233, P=0.012, P=0.008, and P=0.003 for insulin 
sensitivity by paired t-test) or when compared with placebo (P=0.147 for adiponectin and P=0.006 for insulin sensitivity by ANOVA). However, the 
magnitude of these percent changes (glycated hemoglobin, insulin, adiponectin, and QUICKI) were not significantly different among the four different 
doses of atorvastatin despite dose-dependent changes in apolipoprotein B reduction. These effects were not significantly different between patients 
with and without metabolic syndrome/diabetes.
Conclusions: Atorvastatin significantly increased insulin and glycated hemoglobin levels and reduced insulin sensitivity in hypercholesterolemic 
patients with metabolic syndrome/diabetes independent of dosage and the extent of apolipoprotein B reduction.
